Sight Sciences, Inc.
NASDAQ•SGHT
CEO: Mr. Paul Badawi
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-07-15
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact Information
4040 Campbell Avenue, Suite 100, Menlo Park, CA, 94025, United States
877-266-1144
Market Cap
$342.08M
P/E (TTM)
-7.3
32.4
Dividend Yield
--
52W High
$9.24
52W Low
$2.03
52W Range
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q3 2025 Data
Revenue
$19.91M-1.24%
4-Quarter Trend
EPS
-$0.16-27.27%
4-Quarter Trend
FCF
-$8.89M-1719.13%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
$99.66M
$76.05M
$69.04M
Gross Margin (Latest Quarter)
MXCT92.4%
86.4%
83.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| FBRX | $418.27M | -11.5 | -75.6% | 0.0% |
| SGHT | $342.08M | -7.3 | -61.6% | 35.0% |
| PROF | $248.26M | -6.3 | -86.8% | 0.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 4, 2026
EPS:-$0.17
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $19.91M-1.2%|EPS: $-0.16-27.3%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $19.56M-8.5%|EPS: $-0.23-8.0%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $17.51M-9.1%|EPS: $-0.28-15.2%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 7, 2025|Revenue: $79.87M-1.5%|EPS: $-1.03+9.6%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $20.16M+0.7%|EPS: $-0.22-18.5%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 2, 2024|Revenue: $21.37M-9.0%|EPS: $-0.25-16.7%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 6, 2024|Revenue: $19.27M+2.3%|EPS: $-0.33-5.7%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 13, 2024|Revenue: $81.06M+13.6%|EPS: $-1.14+36.7%Miss